the patent for gene

I agree with the Supreme Court’s decision in the 2013 Myriad Genetics case on gene patents. Myriad has a monopoly on BRCA2 and BRCA1 gene research. The aforementioned genes have been linked to the progression of ovarian and breast cancer. In either case, Myriad is granted a patent, granting it the power to exclude anyone from doing medical testing and gene analysis. They will choose their own price. As a result, it would be difficult for women who are at risk of developing ovarian and breast cancer to perform these scans while still having a second opinion (Ingram, 2014). Other scientists’ diagnostic and research tests are significant for forming crucial medical decisions.

It stemmed from precise patents of Myriad for the BRCA2 as well as BRCA1 genes. When these genes mutate, the chances of developing cancers of the breast and ovarian likewise increase (Ingram, 2014). Scientists state that not all women with mutated BRCA2 and BRCA1 genes will develop these cancers, though they are at a more greater risk. Approximately 12% of women will get breast cancer throughout their lives, on the word of the National Cancer Institute, however roughly 60% of women who have dangerous BRCA2 and BRCA1 mutation will grow the disorder (Ingram, 2014). When it comes to ovarian cancer, the lifetime risk for most women is 1.4%, however, for females who acquired the defective BRCA genes right from birth, the danger approximation rises to 15% to 40%. Thus, I support the Supreme Court ruling on gene patents in the 2013 Myriad genetics case

Reference

Ingram, T. (2014). Association for Molecular Pathology v. Myriad Genetics, Inc.: The Product of Nature Doctrine Revisited. Berkeley Tech. LJ, 29, 385.